Toll-free:400-690-0195 English 中文版
RNAi technology has broad application prospects in a challenging post-genome era, and it will create a new technological revolution in biomedical research. The chemically-synthetic siRNA gene drug development will become a promising new industry.
Company Introduction

GenePharma (NEEQ: 430601) is a biotechnology company focusing on RNA based technologies and Pharmaceuticals. The company develops and provides innovative, reliable, high quality RNA related products, research and development (R&D) services.Our culture is defined by clear values: Integrity, Respect, Collaboration, and Innovation.

GenePharma has established a comprehensive RNA manufacturing facility, and provides a wide range of open-access technology platforms and services including RNAi, gRNA, mRNA therapeutics, RNA biomarkers. These are all designed to enable efficient development of medicines for customers and support for contract researchprograms.The company's technology uses RNA made of nucleotide analogs targeting the key genes to produce therapeutic effect, synthetic gRNA based genome-editing and mRNA cancer vaccine to treat a wide range of diseases, including those that cannot be effectively treated with existing methods to develop and manufacture drugs.